Checkpoint Therapeutics logo
Checkpoint Therapeutics CKPT

Quarterly report 2025-Q1
added 05-13-2025

report update icon

Checkpoint Therapeutics Cash Flow 2011-2026 | CKPT

Annual Cash Flow Checkpoint Therapeutics

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-31.1 M -47.6 M -57.6 M -26.3 M -16.6 M -21.4 M -25.8 M -15.5 M -9.95 M -1.11 M - - - -

Accounts Payables

6.09 M 6.57 M 11.5 M 16.1 M 3.44 M 3.08 M 9.75 M 3.64 M 2.47 M 917 K - - - -

All numbers in USD currency

Quarterly Cash Flow Checkpoint Therapeutics

2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-11.7 M - - - -6.47 M - - - -14 M - -42.3 M -30.8 M -19.6 M - -16.8 M -10.4 M -4.66 M - -11.6 M -6.7 M -4.54 M - -16.6 M -13.2 M -8.2 M - -18.2 M -11.7 M -5.21 M - -11.3 M -7.46 M -2.79 M - -5.78 M - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

5.11 M 6.09 M 7.89 M 10.8 M - 6.57 M 7.96 M 8.06 M 14.1 M 11.5 M 13 M 12.6 M 9.86 M 16.1 M 7.81 M 5.08 M 3.53 M 3.44 M 3.44 M 3.44 M 3.44 M 3.08 M 3.08 M 3.08 M 3.08 M 9.75 M 9.75 M 9.75 M 9.75 M 3.64 M - - - 2.47 M - - - 917 K - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Checkpoint Therapeutics, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
BioNTech SE BioNTech SE
BNTX
$ 96.98 -6.26 % $ 27.2 B germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 5.16 4.56 % $ 820 M britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Cerus Corporation Cerus Corporation
CERS
$ 2.73 34.49 % $ 520 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 21.96 -2.2 % $ 3.64 B usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.71 -1.45 % $ 114 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.92 -2.83 % $ 259 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 17.54 -4.02 % $ 56.1 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.0 -5.96 % $ 4.94 M israelIsrael
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
- -9.21 % $ 2.55 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
- -5.68 % $ 8.28 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.79 1.66 % $ 27.9 M israelIsrael
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA